I

n a boost for Pfizer (PFE), a U.K. appeals tribunal ruled against an antitrust watchdog that had fined the big drug maker and a small generic company for alleged price gouging in connection with an epilepsy pill. As a result, the case was referred back to the U.K. Competition and Markets Authority for further consideration, although the agency may appeal the decision.

Here’s the back story: In late 2016, the CMA had fined Pfizer and Flynn Pharma a record $113 million for deliberately exploiting their dominant market positions by jacking up the price of the epilepsy drug. In explaining the decision, the agency maintained the companies caused the U.K. National Health Service to unnecessarily pay “excessive” prices. Pfizer’s share of the fine was $106 million. Both companies had appealed.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy